|
시장보고서
상품코드
1339255
한센병 치료제 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 약물 유형별, 질병 유형별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2023-2032년)Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 세계 한센병 치료제 시장 규모는 2032년까지 50억 33만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 향후 시장 성장에 대한 분석을 제공합니다.
피부 질환의 유병률 증가로 인해 한센병 치료제 수요가 빠르게 증가하고 있습니다. 건선이나 한센병과 같은 피부 질환의 유병률은 중국이나 인도와 같은 국가에서 증가하고 있으며, 이는 시장에 박차를 가하고 있습니다. 세계보건기구(WHO)에 따르면, 약 120개국에서 한센병 환자가 발생하고 있으며, 연간 20만 건 이상의 한센병 환자가 보고되고 있습니다. 수억 명의 사람들이 피부 NTDs를 앓고 있습니다.
또 다른 NTD 중 하나인 한센병은 주로 외딴 농촌 지역에 거주하는 소외된 사람들의 생활수준을 떨어뜨리고, 엄청난 불편함, 고통, 낙인, 정신적 고통을 초래하고 있습니다. 높은 발병률로 인해 세계 일부 지역에서는 높은 발병률과 높은 감염률을 보이고 있습니다. 지난 20년간 WHO는 약 1,600만 명의 한센병 환자가 치료를 받은 것으로 추정하고 있습니다. 따라서 피부병의 유병률 증가와 NTD의 확산은 한센병 치료제에 대한 수요를 증가시켜 예측 기간 동안 시장 성장을 주도할 것으로 보입니다.
WHO에 따르면, NTDs에 대한 개입이 필요한 사람의 수는 지난 10년간 25% 감소했으며, 2020-2021년 사이에 약 8,000만 명이 감소할 것이라고 합니다. 또한, 장애로 인한 삶의 기간으로 측정한 질병 부담도 지속적으로 감소하고 있으며, 2016년부터 2019년까지 매년 10억 명 이상이 치료를 받고 있으며, 2022년 말까지 47개국이 최소 1개 이상의 NTD를 퇴치할 것으로 예상하고 있습니다.
그러나 코로나19 팬데믹은 NTD 프로그램에 심각한 영향을 미쳤고, 그 결과 지역 사회 기반 개입의 실행이 감소하고, 의료 시설이 제공하는 서비스에 대한 접근이 제한되고, 의료 용품 공급망에 악영향을 미치면서 이 유망한 추세가 무너졌습니다. 이 유망한 추세가 무너졌습니다. 그 결과 2019-2020년 사이에 NTD 치료를 받는 사람이 34% 감소했습니다.
한센병 치료제 시장 보고서 하이라이트
주사제 투여 경로 부문은 한센병 치료제의 1차 선택 약물이 댑슨이라는 점에서 예측 기간 동안 높은 CAGR로 성장할 것으로 예상됩니다.
항결핵제는 리팜핀과 같은 약물이 결핵과 한센병 모두를 치료하기 때문에 예측 기간 동안 큰 시장 점유율을 차지할 것으로 예상됩니다.
아태지역은 유병률 증가와 치료 지원 정부 프로그램으로 인해 예측 기간 동안 상당한 CAGR로 성장할 것으로 예상됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 한센병 치료제 시장에 관한 인사이트
- 한센병 치료제 - 업계 현황
- 한센병 치료제 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTLE 분석
- 한센병 치료제 업계 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 한센병 치료제 시장, 약제 클래스별
- 주요 조사 결과
- 서론
- 항균제
- 한센병
- 술혼
- 페나진
- 항결핵약
- 기타
제6장 세계의 한센병 치료제 시장, 질환 유형별
- 주요 조사 결과
- 서론
- 파우치 박테리아성 한센병
- 다균성 한센병
제7장 세계의 한센병 치료제 시장, 투여 경로별
- 주요 조사 결과
- 서론
- 경구
- 주사
- 국소
제8장 세계의 한센병 치료제 시장, 유통 채널별
- 주요 조사 결과
- 서론
- 병원 약국
- 소매 약국
- 드럭스토어
- 온라인 약국
제9장 세계의 한센병 치료제 시장, 지역별
- 주요 조사 결과
- 서론
- 한센병 치료제 시장 평가, 지역별, 2019-2032년
- 한센병 치료제 시장 - 북미
- 북미 : 한센병 치료제 시장, 약제 클래스별, 2019-2032년
- 북미 : 한센병 치료제 시장, 유통 채널별, 2019-2032년
- 북미 : 한센병 치료제 시장, 질환 유형별, 2019-2032년
- 북미 : 한센병 치료제 시장, 투여 경로별, 2019-2032년
- 한센병 치료제 시장 - 미국
- 한센병 치료제 시장 - 캐나다
- 한센병 치료제 시장 - 유럽
- 유럽 : 한센병 치료제 시장, 약제 클래스별, 2019-2032년
- 유럽 : 한센병 치료제 시장, 유통 채널별, 2019-2032년
- 유럽 : 한센병 치료제 시장, 질환 유형별, 2019-2032년
- 유럽 : 한센병 치료제 시장, 투여 경로별, 2019-2032년
- 한센병 치료제 시장 - 영국
- 한센병 치료제 시장 - 프랑스
- 한센병 치료제 시장 - 독일
- 한센병 치료제 시장 - 이탈리아
- 한센병 치료제 시장 - 스페인
- 한센병 치료제 시장 - 네덜란드
- 한센병 치료제 시장 - 러시아
- 한센병 치료제 시장 - 아시아태평양
- 아시아태평양 : 한센병 치료제 시장, 약제 클래스별, 2019-2032년
- 아시아태평양 : 한센병 치료제 시장, 유통 채널별, 2019-2032년
- 아시아태평양 : 한센병 치료제 시장, 질환 유형별, 2019-2032년
- 아시아태평양 : 한센병 치료제 시장, 투여 경로별, 2019-2032년
- 한센병 치료제 시장 - 중국
- 한센병 치료제 시장 - 인도
- 한센병 치료제 시장 - 일본
- 한센병 치료제 시장 - 말레이시아
- 한센병 치료제 시장 - 인도네시아
- 한센병 치료제 시장 - 한국
- 한센병 치료제 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 한센병 치료제 시장, 약제 클래스별, 2019-2032년
- 중동 및 아프리카 : 한센병 치료제 시장, 유통 채널별, 2019-2032년
- 중동 및 아프리카 : 한센병 치료제 시장, 질환 유형별, 2019-2032년
- 중동 및 아프리카 : 한센병 치료제 시장, 투여 경로별, 2019-2032년
- 한센병 치료제 시장 - 사우디아라비아
- 한센병 치료제 시장 - 남아프리카
- 한센병 치료제 시장 - 이스라엘
- 한센병 치료제 시장 - 아랍에미리트(UAE)
- 한센병 치료제 시장 - 라틴아메리카
- 라틴아메리카 : 한센병 치료제 시장, 약제 클래스별, 2019-2032년
- 라틴아메리카 : 한센병 치료제 시장, 유통 채널별, 2019-2032년
- 라틴아메리카 : 한센병 치료제 시장, 질환 유형별, 2019-2032년
- 라틴아메리카 : 한센병 치료제 시장, 투여 경로별, 2019-2032년
- 한센병 치료제 시장 - 멕시코
- 한센병 치료제 시장 - 브라질
- 한센병 치료제 시장 - 아르헨티나
제10장 경쟁 구도
- 확장 및 인수 분석
- 확장
- 인수
- 제휴/협업/합의/공개
- Acme Pharmaceuticals
- Astra Zeneca
- Bayer
- Bristol-Myers
- Cadila Pharmaceuticals
- Eli Lily
- Genetic Pharma
- GSK
- IDPL
- Johnson & Johnson
- Lark Laboratories
- Merck
- Macleods Pharmaceuticals
- Novartis
- Pfizer
- Systopic Laboratories
- Sanofi
- Teva Pharmaceutical
The global Leprosy Treatment market size is expected to reach USD 5,000.33 million by 2032, according to a new study by Polaris Market Research. The report "Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial, Leprostatics, Sulfone, Phenazine, Anti-tubercular Drugs, and Others); By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The demand for leprosy treatment is growing more quickly due to the increasing incidence of skin diseases. The prevalence of skin conditions like psoriasis and leprosy has increased in nations like China and India, which has fueled the market. According to the World Health Organization, around 120 countries have leprosy cases, and more than 200,000 cases are reported yearly. Hundreds of millions of people have skin NTDs.
Additionally, leprosy, an NTD, hurts the standard of living of mainly marginalized populations in remote rural areas and causes immense discomfort, suffering, stigmatization, and mental distress. The prevalence of high occurrences provides that some regions of the world experience both high incidence and high transmission rates. In the past 20 years, the WHO estimates that approximately 16 million leprosy cases have been treated. Therefore, the rising prevalence of skin disease and NTD prevalence has increased the demand for leprosy treatment, driving the market's growth over the forecast period.
As per the WHO, the number of people needing interventions for NTDs has fallen by 25% over the past ten years, by about 80 million people between 2020 and 2021. Additionally, there is a consistent decline in the disease burden measured in years of life with a disability. Between 2016 and 2019, more than one billion individuals received treatment annually. By the end of 2022, 47 nations had eliminated at least one NTD.
However, the COVID-19 pandemic severely affected NTD programs, which resulted in a decrease in the implementation of community-based interventions, a restriction on access to services provided by healthcare facilities, and negative effects on the supply chains for medical supplies, disrupting this promising trend. As a result, between 2019 and 2020, 34% fewer people were treated for NTDs.
Leprosy Treatment Market Report Highlights
The injectable route of administration segment is anticipated to grow at a significant CAGR over the forecast period owing to the drug of first preference for treating leprosy being dapsone.
Anti-tubercular drugs are expected to hold a significant market share over the forecast period due to drugs such as Rifampin treating both TB and leprosy.
Asia-Pacific is expected to grow at a considerable CAGR over the projected period on account of the rising disease prevalence as well as the government programs to support the treatment.
The global players include: Astra Zeneca, Bayer, GSK, Johnson & Johnson, Merck, Pfizer Inc., Systopic Laboratories, Sanofi, and Teva Pharmaceutical.
Polaris Market Research has segmented the Leprosy Treatment market report based on drug class, route of administration, disease type, distribution channel, and region:
Leprosy Treatment, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)
- Antibacterial
- Leprostatics
- Sulfone
- Phenazine
- Anti-tubercular Drugs
- Others
Leprosy Treatment, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)
- Oral
- Injectable
- Topical
Leprosy Treatment, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)
- Paucibacillary Leprosy
- Multibacillary Leprosy
Leprosy Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Leprosy Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Leprosy Treatment Market Insights
- 4.1. Leprosy Treatment - Industry Snapshot
- 4.2. Leprosy Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Technological advancement
- 4.2.1.2. Increasing use of Leprosy Treatment technology in healthcare
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Increasing digitization will restrict the market growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Leprosy Treatment Industry Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Leprosy Treatment Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 5.3. Antibacterial
- 5.3.1. Global Leprosy Treatment Market, by Antibacterial, by Region, 2019-2032 (USD Million)
- 5.4. Leprostatics
- 5.4.1. Global Leprosy Treatment Market, by Leprostatics, by Region, 2019-2032 (USD Million)
- 5.5. Sulfone
- 5.5.1. Global Leprosy Treatment Market, by Sulfone, by Region, 2019-2032 (USD Million)
- 5.6. Phenazine
- 5.6.1. Global Leprosy Treatment Market, by Phenazine, by Region, 2019-2032 (USD Million)
- 5.7. Anti-tubercular Drugs
- 5.7.1. Global Leprosy Treatment Market, by Anti-tubercular Drugs, by Region, 2019-2032 (USD Million)
- 5.8. Others
- 5.8.1. Global Leprosy Treatment Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Leprosy Treatment Market, by Disease Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 6.3. Paucibacillary Leprosy
- 6.3.1. Global Leprosy Treatment Market, by Paucibacillary Leprosy, by Region, 2019-2032 (USD Million)
- 6.4. Multibacillary Leprosy
- 6.4.1. Global Leprosy Treatment Market, by Multibacillary Leprosy, by Region, 2019-2032 (USD Million)
7. Global Leprosy Treatment Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 7.3. Oral
- 7.3.1. Global Leprosy Treatment Market, by Oral, by Region, 2019-2032 (USD Million)
- 7.4. Injectable
- 7.4.1. Global Leprosy Treatment Market, by Injectable, by Region, 2019-2032 (USD Million)
- 7.5. Topical
- 7.5.1. Global Leprosy Treatment Market, by Topical, by Region, 2019-2032 (USD Million)
8. Global Leprosy Treatment Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3. Hospital Pharmacies
- 8.3.1. Global Leprosy Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
- 8.4. Retail Pharmacies
- 8.4.1. Global Leprosy Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
- 8.5. Drug Stores
- 8.5.1. Global Leprosy Treatment Market, by Drug Stores, by Region, 2019-2032 (USD Million)
- 8.6. Online Pharmacies
- 8.6.1. Global Leprosy Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Million)
9. Global Leprosy Treatment Market, by Geography
- 9.1. Key findings
- 9.2. Introduction
- 9.2.1. Leprosy Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
- 9.3. Leprosy Treatment Market - North America
- 9.3.1. North America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.3.2. North America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.3.3. North America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.3.4. North America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.3.5. Leprosy Treatment Market - U.S.
- 9.3.5.1. U.S.: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.3.5.2. U.S.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.3.5.3. U.S.: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.3.5.4. U.S.: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.3.6. Leprosy Treatment Market - Canada
- 9.3.6.1. Canada: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.3.6.2. Canada: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.3.6.3. Canada: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.3.6.4. Canada: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4. Leprosy Treatment Market - Europe
- 9.4.1. Europe: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.2. Europe: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.3. Europe: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.4. Europe: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4.5. Leprosy Treatment Market - UK
- 9.4.5.1. UK: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.5.2. UK: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.5.3. UK: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.5.4. UK: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4.6. Leprosy Treatment Market - France
- 9.4.6.1. France: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.6.2. France: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.6.3. France: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.6.4. France: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4.7. Leprosy Treatment Market - Germany
- 9.4.7.1. Germany: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.7.2. Germany: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.7.3. Germany: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.7.4. Germany: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4.8. Leprosy Treatment Market - Italy
- 9.4.8.1. Italy: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.8.2. Italy: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.8.3. Italy: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.8.4. Italy: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4.9. Leprosy Treatment Market - Spain
- 9.4.9.1. Spain: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.9.2. Spain: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.9.3. Spain: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.9.4. Spain: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4.10. Leprosy Treatment Market - Netherlands
- 9.4.10.1. Netherlands: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.10.2. Netherlands: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.10.3. Netherlands: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.10.4. Netherlands: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.4.11. Leprosy Treatment Market - Russia
- 9.4.11.1. Russia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.4.11.2. Russia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.11.3. Russia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.4.11.4. Russia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.5. Leprosy Treatment Market - Asia Pacific
- 9.5.1. Asia Pacific: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.5.2. Asia Pacific: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.3. Asia Pacific: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.5.4. Asia Pacific: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.5.5. Leprosy Treatment Market - China
- 9.5.5.1. China: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.5.5.2. China.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.5.3. China: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.5.5.4. China: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.5.6. Leprosy Treatment Market - India
- 9.5.6.1. India: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.5.6.2. India.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.6.3. India: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.5.6.4. India: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.5.7. Leprosy Treatment Market - Japan
- 9.5.7.1. Japan: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.5.7.2. Japan.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.7.3. Japan: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.5.7.4. Japan: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.5.8. Leprosy Treatment Market - Malaysia
- 9.5.8.1. Malaysia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.5.8.2. Malaysia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.8.3. Malaysia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.5.8.4. Malaysia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.5.9. Leprosy Treatment Market - Indonesia
- 9.5.9.1. Indonesia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.5.9.2. Indonesia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.9.3. Indonesia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.5.9.4. Indonesia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.5.10. Leprosy Treatment Market - South Korea
- 9.5.10.1. South Korea: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.5.10.2. South Korea.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.10.3. South Korea: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.5.10.4. South Korea: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.6. Leprosy Treatment Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.6.2. Middle East & Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.6.3. Middle East & Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.6.4. Middle East & Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.6.5. Leprosy Treatment Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.6.5.2. Saudi Arabia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.6.5.3. Saudi Arabia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.6.5.4. Saudi Arabia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.6.6. Leprosy Treatment Market - South Africa
- 9.6.6.1. South Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.6.6.2. South Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.6.6.3. South Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.6.6.4. South Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.6.7. Leprosy Treatment Market - Israel
- 9.6.7.1. Israel: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.6.7.2. Israel: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.6.7.3. Israel: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.6.7.4. Israel: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.6.8. Leprosy Treatment Market - UAE
- 9.6.8.1. UAE: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.6.8.2. UAE: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.6.8.3. UAE: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.6.8.4. UAE: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.7. Leprosy Treatment Market - Latin America
- 9.7.1. Latin America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.7.2. Latin America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.7.3. Latin America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.7.4. Latin America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.7.5. Leprosy Treatment Market - Mexico
- 9.7.5.1. Mexico: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.7.5.2. Mexico: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.7.5.3. Mexico: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.7.5.4. Mexico: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.7.6. Leprosy Treatment Market - Brazil
- 9.7.6.1. Brazil: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.7.6.2. Brazil: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.7.6.3. Brazil: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.7.6.4. Brazil: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
- 9.7.7. Leprosy Treatment Market - Argentina
- 9.7.7.1. Argentina: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
- 9.7.7.2. Argentina: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.7.7.3. Argentina: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
- 9.7.7.4. Argentina: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
- 11.1. Acme Pharmaceuticals
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Astra Zeneca
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Bayer
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Bristol-Myers
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Cadila Pharmaceuticals
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Eli Lily
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Genetic Pharma
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. GSK
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. IDPL
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Johnson & Johnson
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Lark Laboratories
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Merck
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13.Macleods Pharmaceuticals
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
- 11.14. Novartis
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
- 11.15. Pfizer
- 11.15.1. Company Overview
- 11.15.2. Financial Performance
- 11.15.3. Product Benchmarking
- 11.15.4. Recent Development
- 11.16. Systopic Laboratories
- 11.16.1. Company Overview
- 11.16.2. Financial Performance
- 11.16.3. Product Benchmarking
- 11.16.4. Recent Development
- 11.17. Sanofi
- 11.17.1. Company Overview
- 11.17.2. Financial Performance
- 11.17.3. Product Benchmarking
- 11.17.4. Recent Development
- 11.18. Teva Pharmaceutical
- 11.18.1. Company Overview
- 11.18.2. Financial Performance
- 11.18.3. Product Benchmarking
- 11.18.4. Recent Development
비교리스트